Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression

Journal of Pediatric Surgery

Volumn 35, Issue 3, 2000, Pages 432-437

  Ara, Tasnim ^a   Kusafuka, Takeshi ^a   Inoue, Masahiro ^a   Kuroda, Seika ^a   Fukuzawa, Masahiro ^a   Okada, Akira ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

MMP 2; MMP 9; Neuroblastoma; Prognosis; Reverse transcription polymerase chain reaction; TIMP 2

Indexed keywords

GELATINASE A; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFANT; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 0034014754     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(00)90208-2     Document Type: Article

References (30)

1. Hoyhtya M, Fridman R, Komarek D, et al: Immunohistochemical localization of matrix metalloproteinase and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56:500-505, 1994
2. Grignon DJ, Sakr W, Toth M, et al: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654-1659, 1996
3. Sier CFM, Kubben FJGM, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74:413-417, 1996
4. Heppner KJ, Matrisian LM, Jensen RA, et al: Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273-282, 1995
5. Zeng ZS, Guillem JG: Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase I mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 72:575-582, 1995
6. Sato H, Kida Y, Mai M, et al: Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7:77-83, 1992
7. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphoma' in humans. Br J Cancer 73:1401-1408, 1996
8. Liabakk NB, Talbot I, Smith RA, et al: Matrix metalloprotease-2 (MMP-2) and matrix metalloproteases-9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190-196, 1996
9. Rao VH, Singh RK, Bridge JA, et al: Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone. Clin Exp Metastasis 15:400-409, 1997
10. Brown PD: Clinical trials of a low molecular weight matrix metalloproteinases inhibitor in cancer. Ann NY Acad Sci 732:217-221, 1994
11. Rabbani SA: Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 12:135-142, 1998
12. MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Can Met Rev 14:351-362, 1995
13. Onisto M, Ricco MP, Scannapieco P, et al: Gelatinase A/TIMP-2 imbalance in lymph node positive breast carcinomas, as measured by RT-PCR. Int J Cancer 63:621-626, 1995
14. Onisto M, Garbisa S, Caenazzo C, et al: Reverse transcription-polymerase chain reaction phenotyping of metalloproteinases and inhibitors involved in tumor matrix invasion. Diagn Mol Pathol 2:74-80, 1993
15. Salomon RN: Introduction to quantitative reverse transcription polymerase chain reaction. Diagn Mol Pathol 4:82-84, 1995
16. Ara T, Fukuzawa M, Kusafuka T, et al: Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: Association with tumor progression and clinical outcome. J Pediatr Surg 33:1272-1278, 1998
17. Evans AE, D'Angio GJ, Randolyph J: A proposed staging for children with neuroblastoma: Children's cancer study group A. Cancer 27:374-378, 1971
18. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
19. Murphy LD, Herzog CE, Rudick JB, et al: Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29:10351-10356, 1990
20. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75, 1997
21. Gohji K, Fujimoto N, Ohkawa J, et al: Imbalance between serum matrix metalloproteinase-2 its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 74:650-655, 1998
22. Nuovo GJ, MacConnell PB, Simsir A, et al: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55:267-275, 1995
23. Sato H, Takino T, Kinoshita T, et al: Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT-1-MMP). FEBS Lett 385:238-240, 1996
24. Sato H, Takino T, Okada Y, et al: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61-66, 1994
25. Nakahara H, Howard L, Thompson EW, et al: Transmembrane/ cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A 94:7959-7964, 1997
26. Monsky WL, Kelly T, Lin CY, et al: Binding and localization of Mr 72,000 matrix metalloproteinase at cell surface invadopedia. Cancer Res 53:3159-3164, 1993
27. Sugiura Y, Shimada H, Seeger RC, et al: Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58:2209-2216, 1998
28. Sakakibara M, Koizumi S, Saikawa Y, et al: Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 85:231-239, 1999
29. Wason SA, Morris TM, Parsons SL, et al: Therapeutic effect of the matrix metalloproteinases inhibitor, batimastat, in human colorectal cancer ascites model. Br J Cancer 74:1354-1358, 1996
30. Price A, Shi Q, Morris D, et al: Marked inhibition of the tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinases inhibitor AG3340. Clin Can Res 5:845-854, 1999